Abcam, ab275522, Human PDGFRA knockout SH-SY5Y cell lysate

Size: 1Kit
PDGFRA KO cell lysate available now. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 67 bp deletion in exon 3.
Key facts
Cell type:SH-SY5Y,
Species or organism:Human,
Tissue:Bone marrow,
Knockout validation:Immunocytochemistry,Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 67 bp deletion in exon 3,
Disease:Neuroblastoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PDGFRA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Immunocytochemistry, Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PDGFR alpha also known as platelet-derived growth factor receptor alpha is a cell surface receptor tyrosine kinase with a mass of approximately 123 kDa. It plays a mechanical role in transmitting signals across the cell membrane initiating cellular responses. PDGFR alpha is widely expressed in mesenchymal cells including fibroblasts and smooth muscle cells. Researchers frequently employ techniques such as PDGFRA IHC and PDGFRA staining to study the localization and expression levels in tissues.
Biological function summary
PDGFR alpha mediates cell proliferation survival and differentiation especially in embryonic development and wound healing. The receptor often forms a complex by dimerizing with itself or with PDGFR beta to activate intracellular signaling cascades. This process is initiated upon ligand binding which triggers autophosphorylation on tyrosine residues. The receptor is also recognized in the detection of PDGFRA with assays such as PDGFRA ELISA.
Pathways
PDGFR alpha significantly affects the MAPK and PI3K/AKT signaling pathways which regulate cellular growth and survival signals. Through these pathways PDGFR alpha interacts with related proteins like SHP-2 and PI3K contributing to signal transduction involved in cellular responses. This role links PDGFR alpha to important cellular processes via its kinase activity and signal integration.
PDGFR alpha is implicated in conditions such as gastrointestinal stromal tumors (GISTs) and idiopathic pulmonary fibrosis (IPF). It connects to proteins such as KIT in GISTs where mutations cause aberrant receptor signaling leading to tumorigenesis. Aberrant PDGFR alpha signaling also associates with IPF a disorder characterized by increased fibroblast proliferation and fibrotic tissue formation. These connections make PDGFR alpha a significant target for research and therapeutic intervention.